These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 38668075)

  • 1. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
    Nathan P; Rajeh A; Noor M; Boldt G; Fernandes R
    Curr Oncol; 2024 Apr; 31(4):2316-2327. PubMed ID: 38668075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates in Uro-Oncology.
    Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
    Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
    J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genitourinary cancers updates: highlights from ASCO 2023.
    Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
    J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in genitourinary malignancies.
    Thana M; Wood L
    Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
    Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
    Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.
    Sganga S; Riondino S; Iannantuono GM; Rosenfeld R; Roselli M; Torino F
    J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
    Pramanik D
    Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Sternschuss M; Sarfaty M
    Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current standards and practice changing studies in genitourinary (GU) cancers-a review of studies in localized/early GU cancers.
    Tan WC; Kanesvaran R
    ESMO Open; 2022 Apr; 7(2):100432. PubMed ID: 35272133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
    Niegisch G
    Methods Mol Biol; 2023; 2684():293-301. PubMed ID: 37410242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic agents for genitourinary cancers.
    Zarrabi K; Paroya A; Wu S
    J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy.
    Aggarwal D; Yang J; Salam MA; Sengupta S; Al-Amin MY; Mustafa S; Khan MA; Huang X; Pawar JS
    Front Immunol; 2023; 14():1203073. PubMed ID: 37671162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates for the treatment of urothelial carcinoma.
    Ravi P; McGregor BA
    Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.